IDH1 and cancer: It has been shown that gain-of-function mutations in IDH in human cancers lead to the production of d-2-hydroxyglutarate (d-2HG), a metabolite that promotes tumorigenesis through epigenetic alterations and can alter T-cell metabolism and impair CD8+ T-cell function [143].